These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34774018)

  • 21. "It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda.
    Alhassan Y; Twimukye A; Malaba T; Myer L; Waitt C; Lamorde M; Colbers A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Womens Health; 2022 Jun; 22(1):246. PubMed ID: 35729541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study.
    Zakumumpa H; Kitutu FE; Ndagije HB; Diana NK; Ssanyu JN; Kiguba R
    BMC Infect Dis; 2021 Dec; 21(1):1222. PubMed ID: 34876050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.
    George JW; Mattingly JE; Roland NJ; Small CM; Lamberty BG; Fox HS; Stauch KL
    Front Immunol; 2021; 12():639378. PubMed ID: 34093527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switch to dolutegravir is well tolerated in Thais with HIV infection.
    Goh OQ; Colby DJ; Pinyakorn S; Sacdalan C; Kroon E; Chan P; Chomchey N; Kanaprach R; Prueksakaew P; Suttichom D; Trichavaroj R; Spudich S; Robb ML; Phanuphak P; Phanuphak N; Ananworanich J;
    J Int AIDS Soc; 2019 Jul; 22(7):e25324. PubMed ID: 31294931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.
    Fernández-Bargiela N; Rotea-Salvo S; Margusino-Framiñán L; Balboa-Barreiro V; Martín-Herranz I; Castro-Iglesias Á; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Míguez-Rey E; Cid-Silva P
    Eur J Hosp Pharm; 2022 Jul; 29(4):207-211. PubMed ID: 33051194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
    Kiiza D; Rostami-Hochaghan D; Alhassan Y; Seden K; Reynolds H; Kaboggoza JP; Taegtmeyer M; Chen T; Challenger E; Malaba T; Wang D; Else L; Hern F; Sharp J; Neary M; Dilly Penchala S; Waitt C; Orrell C; Colbers A; Myer L; Owen A; Rannard S; Khoo S; Lamorde M
    J Antimicrob Chemother; 2024 Sep; 79(9):2334-2342. PubMed ID: 38997229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort.
    Chan P; Goh O; Kroon E; Colby D; Sacdalan C; Pinyakorn S; Prueksakaew P; Reiss P; Ananworanich J; Valcour V; Spudich S; Paul R;
    AIDS Res Ther; 2020 Jan; 17(1):1. PubMed ID: 31907064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamivudine plus dolutegravir as a switch strategy in children: three case reports.
    Labate L; Bartalucci C; Taramasso L; Brucci G; Vena A; Bassetti M; Di Biagio A
    New Microbiol; 2024 May; 47(1):111-115. PubMed ID: 38700892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.
    Namayanja GA; Da Silva JF; Elur B; Nasirumbi PM; Raizes E; Ssempiira J; Nazziwa E; Nabukenya M; Sewanyana I; Balaba J; Ntale J; Calnan J; Birabwa E; Akao J; Mwangi C; Naluguza M; Ahimbisibwe A; Katureebe C; Nabadda S; Nelson L; Dirlikov E
    PLoS One; 2024; 19(6):e0305129. PubMed ID: 38923981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "No One Needs to be Forced": Qualitative Insights on Competing Priorities between Antiretroviral Therapy and Reproductive Health Planning during the Dolutegravir Rollout.
    Maju M; Hassan SA; Bernard C; Maina M; Thorne JG; Komanapalli SA; Humphrey JM; Kerich C; Changwony S; Jakait B; Wools-Kaloustian K; Patel RC
    AIDS Behav; 2024 Nov; 28(11):3719-3732. PubMed ID: 39083152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
    Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;
    J Int AIDS Soc; 2019 Jan; 22(1):e25227. PubMed ID: 30663278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study.
    Zakumumpa H; Kiguba R; Ndagije HB; Ategeka G; Ssanyu JN; Kitutu FE
    BMC Infect Dis; 2022 Aug; 22(1):692. PubMed ID: 35971109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
    Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
    Mmasa KN; Powis K; Sun S; Makhema J; Mmalane M; Kgole S; Masasa G; Moyo S; Gerschenson M; Mohammed T; Legbedze J; Abrams EJ; Kurland IJ; Geffner ME; Jao J
    HIV Med; 2021 Sep; 22(8):715-722. PubMed ID: 34003565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
    Ochanda PN; Lamorde M; Kintu K; Wang D; Chen T; Malaba T; Myer L; Waitt C; Reynolds H; Khoo S
    AIDS Res Ther; 2022 Jun; 19(1):24. PubMed ID: 35672853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.
    Stellbrink HJ; Reynes J; Lazzarin A; Voronin E; Pulido F; Felizarta F; Almond S; St Clair M; Flack N; Min S;
    AIDS; 2013 Jul; 27(11):1771-8. PubMed ID: 23807273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.